Summary.-A single dose of 200 mg/kg razoxane protected mice against the subchronic lethal effects (i.e. within 21 days) of 10 mg/kg daunomycin. When the razoxane dose was split into 2 doses of 100 mg/kg, even better protection against higher doses of daunomycin was obtained. The best protective effect was seen when the razoxane was given 24 h before or simultaneously with the daunomycin, and it was still present, though less, 24 h later.
IT HAS BEEN DEMONSTRATED in a series
of experiments (Herman et al., 1974 (Herman et al., , 1979 that the toxicity of the anthracycline daunomycin (DM) can be greatly reduced by the administration of razoxane (RZ, . Others (Woodman et al., 1975) have found that not only will RZ reduce the toxicity of DM, but it will also enhance its antitumour activity. The mechanism whereby this distinct improvement in the therapeutic ratio of DM is obtained remains unclear, and it seemed of some interest therefore to define it more accurately.
MATERIALS AND METHODS
Drugs.-Daunomycin (DM, Rhone Polenc) was dissolved in 0.9%o saline and used immediately or stored at 4°C for a maximum of 24 h. Razoxane (RZ, Imperial Chemical Inds.) was milled over-night in CMC (0-5%o carboxymethyl cellulose in 0.9% saline) and stored until required at 4°C for not more than 5 days.
Both DM and RZ were injected i.p. into BDF1 (C57/B6 female x DBA/2 male) female mice weighing 18-20 g.
In a single-dose schedule, doses of 50, 100, 150 or 200 mg/kg RZ were given at the same time as 10, 20, 25 or 30 mg/kg DM. In a splitdose schedule, 100 mg/kg RZ was given at 24 and 18 h before 10, 20, 25 or 30 mg/kg DM. In a further experiment, 200 mg/kg RZ was given over a period ranging from 96 h before to 48 h after the administration of 10 mg/kg DM In multiple-dose schedules doses of RZ ranging from 50 to 400 mg/kg were given on Days 1, 5 and 9, and DM (4 or 6 mg/kg) was given 24 h after each RZ dose.
Evaluation of toxicity.-In the single-dose schedules, either the number of days to 100% mortality in each group, or the number of survivors after 21 days was recorded, as mice surviving beyond that time survived indefinitely. In the multiple-dose schedules the number of mice in each group surviving for at least 30 days was noted.
Histopathology. 
RESULTS

Survival of mice after daunomycin and razoxane treatment
In the single-dose schedule, the timing of the dose of RZ in relation to that of DM was found to be important (Fig. 1) .
The protective effect of RZ (200 mg/kg) was greatest when given 24 h before, or at the same time as 10 mg/kg DM, when 6/6 of the mice survived. Survivors were reduced to 4/6 in the groups given RZ 48 h before, or 24 h after DM injection. RZ given more than 48 h before DM was ineffective. RZ (Fig. 6) mucus secretion had greatly increased, so that in one mouse the crypts were distended with mucus and had flattened epithelium (Fig. 7) . In both mice the wall was lined by a thick mucus, trapping epithelial debris. Brunner's glands were only included in the duodenal section of one of these mice, and compared with the control (Fig. 4) (Goldin et al., 1974; Millar et al., 1978) depressing each other's toxicity but at the same time increasing the combined activity. It seems clear from our studies that the acute DM gut toxicity has been drastically reduced by RZ. The protective effect of RZ seems great- er when given before DM, which is perhaps not surprising, but the fact that protection can still clearly be demonstrated when RZ is given 24 h after the DM would seem to indicate that the mechanism involved acts during a similar time course to the renewal of the crypt cells which seem to be chiefly affected. One might speculate therefore that the protective effect of RZ occurred during the replication of the crypt cells. It is not possible from the present experiments to say which drug influences which, but since both drugs are chelating agents it may be that they compete for the same ions or free radicals which may be more involved in the induction of toxicity than in the inhibition of replication.
The limited clinical use of DM is due to the combined drawbacks of modest antitumour activity (except in adult leukaemias), dose-liniting cardiotoxicity and potent carcinogenicity. If these sideeffects could be reduced by simultaneous administration of RZ, the basis for a re-exploration of this drug in cancer treatment might be provided. The possibility of a concomitant increase in activity would make such a re-exploration doubly attractive, particulary in adult acute leukaemia, where although remission rates with current regimes using DM have reached 75-80%, survival for more than 18 months is still uncommon.
